Apricus Biosciences (APRI) Gets Paatent Allowance for Dodecy1-2 by EPO
Tweet
Share
E-mailGet Alerts APRI Hot Sheet
Join SI Premium – FREE
Apricus Biosciences, Inc. (Nasdaq: APRI) reports that the European Patent Office ("EPO") has issued an official decision to allow the Company's patent application entitled, "Method for the Manufacture of Dodecyl 2-(N,N-Dimenthylamino)-Propionate."
The allowed patent application is a divisional of a Company-owned European patent issued in 2000 entitled "Crystalline Salts of Dodecyl 2-(N,N-Dimenthylamino)-Propionate" that protects the DDAIP.HCl compound and method of manufacture.
The recently allowed divisional application covers the transesterification approach to synthesizing DDAIP (the main chemical penetration enhancing compound used in the Company's NexACT(R) technology) and results in a product containing relatively lower levels of by-products and unreacted reactants, which are undesirable and difficult to remove by conventional methods. This may result in significant cost savings on the finished product. This patent, when issued, will provide European patent protection to March 2020 and will be the 16th patent granted for this technology worldwide, with three applications pending in this patent family.
The allowed patent application is a divisional of a Company-owned European patent issued in 2000 entitled "Crystalline Salts of Dodecyl 2-(N,N-Dimenthylamino)-Propionate" that protects the DDAIP.HCl compound and method of manufacture.
The recently allowed divisional application covers the transesterification approach to synthesizing DDAIP (the main chemical penetration enhancing compound used in the Company's NexACT(R) technology) and results in a product containing relatively lower levels of by-products and unreacted reactants, which are undesirable and difficult to remove by conventional methods. This may result in significant cost savings on the finished product. This patent, when issued, will provide European patent protection to March 2020 and will be the 16th patent granted for this technology worldwide, with three applications pending in this patent family.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Hinge Health signs $86M office lease in San Francisco
- Solowin Holdings marks 10 years, expands into stablecoins and AI
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
